BioNTech and BMS report 36.7% response rate for pumitamig in second-line lung cancer at ESMO
SentiSense · Published · Updated
BioNTech and Bristol Myers Squibb reported Phase 2 ROSETTA Lung-107 data at ESMO 2026: pumitamig plus docetaxel produced a 36.7% confirmed response ra...
Sign in to read the full story. Free accounts include 20 full reads a month.
Powered by SentiSense - Intelligent Market Analysis